Cephalon CEPH
-
Teva's CEO Thinks China Is A 'Natural Fit'
… though it emerged from a decade of blockbuster deals with a market capitalization of just $32.7 billion. Teva acquired Cephalon for $6.8 billion in 2011, even though its major products were Complete Story »
-
Why Retirement Funds Fall Short
Cephalon CEPH announced Monday that Gabitril did not ..... United States for partial seizures, but Cephalon had been working toward expanding the ..... back of regulatory delays for Sparlon, Cephalon 's drug for attention-deficit hyperactivity …
-
New Morningstar Analyst Report for Teva Pharmaceutical Industries Ltd.
… balance sheet, in our opinion. Teva's acquisition of Cephalon and the appointment of Jeremy Levin as the company's ..... aggressive behavior. Bolstered by its acquisition of Cephalon , Teva also plans to expand its innovative branded pharmaceutical …
-
UPDATE 1- Cephalon wins US court appeal on cancer drug patents
NEW YORK, Feb 14 (Reuters) - A federal appeals court on Thursday said two Cephalon Inc patents related to the cancer drug Fentora are valid, overturning part of a lower court order against the unit of Israel's Teva Pharmaceutical Industries Ltd .
-
US appeals court says Watson did not infringe Cephalon patents
NEW YORK, Feb 14 (Reuters) - A U.S. appeals court reversed part of a ruling in favor of Watson Pharamaceutials over Cephalon in patent lawsuit over the cancer drug Fendora.
-
Teva Reports Disappointing News for Nuvigil Study in Bipolar Disorder
… offset upcoming branded and generic competition for Copaxone. These events also raise our concern over the wisdom of the Cephalon acquisition. For now, however, we remain optimistic that Teva will succeed with the higher value products in its pipeline …
-
Teva Highlights Plan to Overcome Copaxone and Generic Industry Headwinds
… conditions and pain) and respiratory products. This isn't particularly surprising, since these are the areas where Cephalon 's and Teva's capabilities in research and marketing had the most overlap, in our view. In light of Copaxone's …
-
New Morningstar Analyst Report for Valeant Pharmaceuticals International Inc.
… confidence in the Medicis transaction. The firm has made news for large transactions such as its Biovail merger, its bid for Cephalon , and now the Medicis deal, but it prefers to acquire small products that are either unprofitable or only slightly profitable …
-
Teva Pharmaceuticals: Valuation Is Too Depressed On Worries About Copaxone
… took another $481 million charge after reviewing its R&D portfolio. The R&D charge was related to the purchase of Cephalon last year, as some drugs have less potential than previously Complete Story »
-
Valeant: Ready To Leap Long-Term On Latest Acquisition
… The acquisition is only the latest in a series of mergers and takeovers for the company after its hostile takeover for Cephalon failed last year. Valeant had bid $5.7 billion. Teva Pharmaceutical Industries ( TEVA ) won the bid at $6.2 billion …